Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Launched by CAN-FITE BIOPHARMA · Jan 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called namodenoson for patients with advanced liver cancer, specifically hepatocellular carcinoma (HCC), who also have a type of liver damage known as Child-Pugh Class B7 cirrhosis. The trial aims to see if namodenoson is more effective than a placebo (a treatment that does not contain the active drug) for patients whose cancer has not responded to previous treatments. If you're at least 18 years old and have advanced liver cancer that has progressed after at least one prior treatment, you may be eligible to participate.

Participants in the trial can expect to receive either namodenoson or a placebo, and they will be closely monitored for both the effectiveness of the treatment and any side effects. To qualify for the study, participants need to have certain health conditions and lab results, including specific blood counts and liver function tests. It’s important to note that those with more severe liver conditions or other serious health issues may not be eligible. If you’re considering joining this trial, it’s a great opportunity to potentially access a new treatment while contributing to important research in liver cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males and females at least 18 years of age.
• 2. Diagnosis of HCC:
• • For patients without cirrhosis at the time of diagnosis, histologic confirmation is required (archival tissue is acceptable).
• • For patients with underlying cirrhosis at the time of diagnosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Marrero 2018).
• • 3. HCC is advanced (i.e., treatment-refractory or metastatic) and no standard therapies are expected to be curative.
• • 4. HCC has progressed on at least 1, but no more than 2, prior systemic treatment regimens; prior locoregional therapy is allowed.
• • 5. Barcelona Clinic Liver Cancer (BCLC) Stage B or C (Llovet 1999).
• • 6. Prior HCC treatment was discontinued for at least 2 weeks prior to the Baseline Visit.
• • 7. Measurable disease by RECIST v1.1 (Eisenhauer 2009).
• • 8. ECOG PS of ≤ 1.
• • 9. Cirrhosis classified as CPB7; if ascites is used as a scoring criterion, it must be classified as Grade ≥2 by the Clinical Practice Guidelines of the European Association for the Study of the Liver (EASL 2010).
• 10. The following laboratory values must be documented within ten days prior to the first dose of study drug:
• • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
• • Platelet count at least 75 × 10\^9/L
• • Creatinine clearance at least 50 mg/dL (estimated glomerular filtration rate by the Cockcroft-Gault or the Modification of Diet in Renal Disease methods)
• • AST and ALT ≤ 5 × the upper limit of normal (ULN)
• • Total bilirubin ≤ 3.0 mg/dL
• • Serum albumin ≥ 2.8 g/dL.
• • 11. Life expectancy of ≥ 6 weeks.
• • 12. For women of childbearing potential, negative serum pregnancy test result.
• • 13. Provide written informed consent to participate.
• • 14. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other trial-related procedures.
• Exclusion Criteria:
• • 1. Receipt of \>2 prior systemic drug therapies for HCC.
• • 2. Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids \> 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial.
• • 3. Locoregional treatment within 4 weeks prior to the Baseline Visit.
• • 4. Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.
• • 5. Use of any investigational agent within 4 weeks prior to the Baseline Visit.
• • 6. Concomitant use of P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) inhibitors and/or substrates with a narrow therapeutic index unless the medication can be taken at least 3 hours before or after taking the investigational product (see Section 12.2).
• • 7. Child-Pugh Class A, B8/9, or C cirrhosis.
• • 8. Hepatic encephalopathy.
• • 9. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion within 4 weeks prior to the Baseline Visit.
• • 10. Uncontrolled or clinically unstable thyroid disease, per judgment of the Principal Investigator.
• • 11. Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
• • 12. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
• • 13. Liver transplant.
• • 14. Active malignancy other than HCC.
• • 15. Uncontrolled arterial hypertension or congestive heart failure (New York Heart Association Classification 3 or 4).
• • 16. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
• • 17. History of, or ongoing, cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to \> 470 msec (patients with bundle branch block will not be excluded for QTc reasons).
• • 18. Pregnant or lactating female.
• • 19. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Investigator, are effective and adequate for the patient's circumstances while on study drug.
• • 20. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug and for 3 months afterward.
• • 21. Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with trial participation or study drug administration; may interfere with the informed consent process and/or with compliance with the requirements of the trial; or may interfere with the interpretation of trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.